Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-

valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population -

**Supplementary Material** 

Jeffrey S. Berger<sup>1</sup>; Veronica Ashton<sup>2</sup>; François Laliberté<sup>3</sup>; Guillaume Germain<sup>3</sup>; Brahim Bookhart<sup>2</sup>;

Dominique Lejeune<sup>3</sup>; Julien Boudreau<sup>3</sup>; Patrick Lefebvre<sup>3</sup>; Matthew R. Weir<sup>4</sup>

<sup>1</sup> New York University School of Medicine, New York, NY, USA;

<sup>2</sup> Janssen Scientific Affairs, LLC, Titusville, NJ, USA;

<sup>3</sup> Groupe d'analyse, Ltée, Montréal, Québec, Canada;

<sup>4</sup> University of Maryland School of Medicine, Baltimore, MD, USA

Corresponding author: Guillaume Germain, Groupe d'analyse, Ltée


1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, Québec, H3B 0G7 Canada

Phone: 514-394-4446; E-mail: guillaume.germain@analysisgroup.com

Number of Figures/Tables: 2 supplementary figures

1

S1 Figure. Healthcare Resource Utilization Among Weighted Rivaroxaban and Warfarin Cohorts — Up to 24 Months of Follow-Up<sup>1</sup>



<sup>\*</sup>p<0.001

CI confidence intervals; ER emergency room; OP outpatient


## Notes:

<sup>&</sup>lt;sup>1</sup>The observation period spans from the index date up to the treatment discontinuation, a switch to/addition of another oral anticoagulant, 24 months (sensitivity analysis) post-index, death, end of eligibility, or end of data availability, whichever occurs first

<sup>&</sup>lt;sup>2</sup>Rate ratios are calculated from Poisson regression models

<sup>&</sup>lt;sup>3</sup>CIs and p-values are generated using a non-parametric bootstrap procedure with 499 replications

S2 Figure. Healthcare Costs Among Weighted Rivaroxaban and Warfarin Cohorts — Up to 24 Months of Follow-Up<sup>1</sup>



CI confidence intervals; ER emergency room; OP outpatient; PPY per patient-year

<sup>&</sup>lt;sup>1</sup>The observation period spans from the index date up to the treatment discontinuation, a switch to/addition of another oral anticoagulant, 24 months (sensitivity analysis) post-index, death, end of eligibility, or end of data availability, whichever occurs first

<sup>&</sup>lt;sup>2</sup>CIs and p-values are generated using a non-parametric bootstrap procedure with 499 replications